Popular Weight-Loss and Type-2 Diabetes Drug Ozempic Launched in India: Check Price

Danish pharmaceutical giant Novo Nordisk has launched its widely known drug Ozempic (semaglutide injection) in India. The medication is primarily prescribed for the treatment of Type-2 diabetes, but it has gained global attention for its significant weight-loss benefits.

Ozempic is now available in India in 0.25 mg, 0.50 mg, and 1 mg doses, offered in an easy-to-use FlexTouch pen. The injection is administered once a week. The starting dose of 0.25 mg has been priced at approximately Rs 2,200 per week. According to the company, the drug is intended for adults with uncontrolled Type-2 diabetes, to be used alongside a healthy diet and regular exercise.

Speaking about the launch, Novo Nordisk India Managing Director Vikrant Shrotriya said, “With Ozempic, we aim to provide people living with Type-2 diabetes in India access to an innovative and effective treatment option. The drug not only helps in better glycaemic control but also supports meaningful weight management and offers long-term cardiovascular and kidney protection.” He emphasized that Ozempic is being marketed in India strictly as a treatment for Type-2 diabetes.

On pricing, Shrotriya noted that Novo Nordisk has adopted a carefully considered strategy for the Indian market, keeping the cost highly competitive compared to global prices. He also pointed out that Wegovy, a higher-dose semaglutide injection (2.4 mg) approved for weight loss, is already available in India through a partnership with Emcure Pharma.

The launch comes at a crucial time, given India’s growing diabetes burden. According to World Health Organization (WHO) estimates, around 101 million people in India are living with diabetes, making it the second-highest globally after China. In addition, nearly 136 million people are pre-diabetic, while about 254 million are affected by general obesity.